CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)

CIBRA Capital Ltd disclosed a buy of 1,476,861 shares of Amicus Therapeutics (NASDAQ:FOLD) in its April 24, 2026, SEC filing, an estimated $21.17 million trade based on quarterly average pricing.According to its SEC filing dated April 24, 2026, CIBRA Capital Ltd increased its holding in Amicus Therapeutics by 1,476,861 shares during the first quarter. The estimated transaction value was $21.17 million, calculated using the average closing price for the quarter. The value of the position at quarter-end rose by $21.40 million, which reflects both the new shares acquired and the underlying share price appreciation.Amicus Therapeutics, Inc. is a biotechnology company specializing in the discovery, development, and commercialization of therapies for rare diseases. With a focus on precision medicines and a robust pipeline, the company leverages scientific expertise and strategic collaborations to address unmet medical needs. Its established commercial presence and targeted approach provide a competitive edge in the rare disease therapeutics market.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool